Table 1. Neither NMDA nor AMPA Receptor mRNA Expression was Significantly Altered in MPFC or Hippocampus by GLYX-13 (3 mg/kg IV) or Ketamine (10 mg/kg IV), as Measured by Microarray and/or qRT-PCR Analyses.

Microarray
Data is expressed as fold change relative to vehicle
	NR1	NR2A	NR2B	NR2C	NR2D	GluR1	GluR2
MPFC, 1 h
GLYX-13	1.08	0.90	0.95	1.00	0.99	0.97	0.99
Ketamine	1.03	0.85	0.96	0.99	1.00	1.03	0.95
MPFC, 24 h
GLYX-13	1.10	0.87	0.98	1.07	0.99	0.87	1.18
Ketamine	1.03	0.85	0.93	1.07	0.98	0.95	1.04

qRT-PCR
Data is expressed as mean±SEM % of control levels
	NR1	NR2A	NR2B	GluR1
MPFC, 1 h
Vehicle	100±8	100±6	100±9	100±12
GLYX-13	82±3	97±2	92±2	88±6
Ketamine	78±17	83±15	73±13	90±13
MPFC, 24 h
Vehicle	100±19	100±11	100±12	100±23
GLYX-13	93±10	99±11	100±8	75±10
Ketamine	75±5	82±5	80±5	62±3
Hippocampus, 1 h
Vehicle	100±23	100±27	100±23	100±24
GLYX-13	76±22	73±20	84±24	83±20
Ketamine	115±14	103±18	136±20	105±18
Hippocampus, 24 h
Vehicle	100±16	100±14	100±15	100±16
GLYX-13	105±7	87±7	97±7	84±9
Ketamine	94±8	73±7	69±6	87±8

n=5–6 per group.